Machet L, Callens A, Mercier E, Gargot S, Lorette G, Vaillant L
Service de Dermatologie, CHU Trousseau, Tours.
Ann Dermatol Venereol. 1996;123(5):328-30.
Dapsone is a drug widely prescribed in dermatology. It can lead to undesirable side effects including hematologic disorders.
A patient with dermatitis herpetiformis was treated with dapsone. Agranulocytosis developed 6 weeks later and was revealed by fever and pneumonia which resolved under antibiotics. The agranulocytosis regressed without specific treatment after drug withdrawal. Blood counts returned to normal 2 weeks later.
Dapsone-induced agranulocytosis is in common (1/10,000 to 1/20,000). The drug is widely prescribed, particularly for leprosy. Nevertheless, when dapsone is prescribed for dermatitis herpetiformis, the risk of agranulocytosis increases 25-fold reaching 1/400. The indication for dapsone must always made carefully, with surveillance of the blood counts every 15 days during the first 3 months of treatment for dermatitis herpetiformis.
氨苯砜是皮肤科广泛使用的一种药物。它可导致包括血液系统疾病在内的不良副作用。
一名疱疹样皮炎患者接受了氨苯砜治疗。6周后发生粒细胞缺乏症,表现为发热和肺炎,经抗生素治疗后缓解。停药后粒细胞缺乏症未经特殊治疗而消退。2周后血细胞计数恢复正常。
氨苯砜引起的粒细胞缺乏症很常见(1/10000至1/20000)。该药物被广泛使用,尤其是用于治疗麻风病。然而,当氨苯砜用于治疗疱疹样皮炎时,粒细胞缺乏症的风险增加25倍,达到1/400。必须谨慎确定氨苯砜的用药指征,在治疗疱疹样皮炎的前3个月期间,每15天监测一次血细胞计数。